Effects of Eicosapentaenoic Acid vs Eicosapentaenoic/Docosahexaenoic Acids on Cardiovascular Mortality
JACC: Advances · 2025-10 · 4 (10) · 102149
DOI: 10.1016/j.jacadv.2025.102149 ↗Kurz gefasst
Fachartikel in der Zeitschrift JACC: Advances, 2025-10. Verfasst von John P Sheppard und 8 weiteren Autor:innen. Beteiligte Einrichtung: Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Purified eicosapentaenoic acid (EPA) and mixed eicosapentaenoic/docosahexaenoic acids (EPA/DHA) are omega-3 polyunsaturated fatty acids (n-3 PUFAs) of interest for preventing cardiovascular disease (CVD) as adjunct to statins. Randomized clinical trial (RCT) evidence continues to emerge, including data from the RESPECT-EPA (Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy-Statin and Eicosapentaenoic Acid) trial, but n-3 PUFAs' roles in prevention remains controversial. OBJECTIVES: The objective of the study was to assess the efficacy of EPA vs EPA/DHA compared to the standard preventive therapy across published RCTs investigating the use of n-3 PUFAs for primary or secondary prevention of CVD. METHODS: Following a prespecified protocol registered in the PROSPERO database (CRD42023390587), we identified RCTs reporting CVD-attributable mortality in patients randomized to EPA, EPA/DHA, or a standard preventive therapy for primary or secondary CVD prevention. We used random effects meta-analysis to estimate pooled HRs of CVD-attributable mortality achieved with EPA or EPA/DHA relative to the standard preventive therapy. RESULTS: Sixteen RCTs met the inclusion criteria, representing 127,771 patients in total (41% women, mean age 64 ± 5 years). Median follow-up was 3.7 years (IQR: 2.7-5.0 years). Compared to the standard preventive therapy, CVD-attributable mortality was significantly reduced with purified EPA (HR: 0.79 [95% CI: 0.67-0.94]; P = 0.006); this effect was less for EPA/DHA (HR: 0.92 [95% CI: 0.84-1.00]; P = 0.044). CONCLUSIONS: EPA lowered incident CVD-attributable mortality in RCTs investigating its use for primary or secondary CVD prevention. Relative to EPA, benefits reported with EPA/DHA were attenuated. Although more work is needed to understand these differences, EPA should preferentially be used in cardiovascular conditions for which it is indicated.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
- University at Buffalo, Buffalo, New York, USA.
- Lundquist Institute/Harbor-UCLA Medical Center, Torrance, California, USA.
- Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Lundquist Institute/Harbor-UCLA Medical Center, Torrance, California, USA. Electronic address: mbudoff@lundquist.org.
- California Cardiovascular Institute, Fresno, California, USA.
Zitieren
APA
Sheppard, J. P., Palatnic, L., Lakshmanan, S., Drago, T., Bhogal, J., Roy, S. K., Bhatt, D. L., Budoff, M. J., & Nelson, J. R. (2025). Effects of Eicosapentaenoic Acid vs Eicosapentaenoic/Docosahexaenoic Acids on Cardiovascular Mortality. JACC: Advances, 4(10), 102149. https://doi.org/10.1016/j.jacadv.2025.102149
Vancouver
Sheppard JP, Palatnic L, Lakshmanan S, Drago T, Bhogal J, Roy SK, et al. Effects of Eicosapentaenoic Acid vs Eicosapentaenoic/Docosahexaenoic Acids on Cardiovascular Mortality. JACC: Advances. 2025;4(10):102149. doi:10.1016/j.jacadv.2025.102149
BibTeX
@article{Sheppard2025,
author = {Sheppard, John P and Palatnic, Leonard and Lakshmanan, Suvasini and Drago, Thomas and Bhogal, Jaspreet and Roy, Sion K and Bhatt, Deepak L and Budoff, Matthew J and Nelson, John R},
title = {Effects of Eicosapentaenoic Acid vs Eicosapentaenoic/Docosahexaenoic Acids on Cardiovascular Mortality},
journal = {JACC: Advances},
year = {2025},
volume = {4},
number = {10},
pages = {102149},
doi = {10.1016/j.jacadv.2025.102149}
}
EUVIMED